Skip to main content

Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial

In brief

Four pneumococcal vaccine doses raised broad responses from 3% to 16%

In rituximab-treated patients with vasculitis, four doses of the conjugate vaccine followed by a polysaccharide vaccine increased the share responding to 7 to 9 of 12 serotypes at six months to 16%, from 3% with the standard schedule. No patient responded to 10 to 12 serotypes, and responses waned over time, so the clinical protection and durability remain uncertain.

Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (Q1)
Published
10 November 2026
Study design
Phase 2 randomized trial (exploratory)
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Benjamin Terrier, Laura Richert, Grégory Pugnet, Olivier Aumaître, Olivier Moranne, Noémie Huchet, et al.
PMID
43008934
DOI
10.1016/j.cmi.2026.11.004

Why clinicians should know about it

  • Picked for Immunology and Allergy (paper of the day, 12 November 2026): Randomized trial guides pneumococcal vaccination during rituximab immunosuppression

Abstract

OBJECTIVES: To assess whether reinforced pneumococcal vaccination strategies improve immunogenicity in patients with ANCA-associated vasculitis (AAV) receiving rituximab. METHODS: PNEUMOVAS was a multicentre, open-label, randomized phase 2 superiority trial. Between February 2018 and May 2020, adults with newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis scheduled for rituximab induction were randomized (1:1:1) to: standard vaccination (Arm A: one PCV13 dose at day 0 followed by PPV23 at month 5), reinforced regimen 1 (Arm B: two PCV13 doses at day 0 and two at day 7 followed by PPV23), or reinforced regimen 2 (Arm C: four PCV13 doses at day 0 followed by PPV23). The primary endpoint was the breadth of the ELISA antibody response at month 6, categorized as a response to 0-3, 4-6, 7-9, or 10-12 of 12 shared serotypes, and analyzed with an age-adjusted proportional odds model in the modified intention-to-treat population. RESULTS: Of 120 planned patients, 96 were randomized (30, 32, and 34 in Arms A, B, and C) and 95 were analyzed (median age 62 years; 47/95 [49.5%] male; median follow-up 17.9 months). At month 6, 1/30 (3.3%), 5/32 (15.6%), and 2/33 (6.1%) participants in Arms A, B, and C responded to 7-9 serotypes, and none to 10-12. Compared with the standard regimen, Arm B significantly improved the breadth of the response (proportional OR 4.14, 97.5% CI 1.08 to 15.88; p=0.018), whereas Arm C showed a non-significant trend (pOR 3.08, 97.5% CI 0.80 to 11.92). Reinforced schedules also improved opsonophagocytic activity for several serotypes. Vaccine responses declined over time in all groups. Vaccination was overall well tolerated, with no vaccine-related serious adverse events. CONCLUSIONS: In AAV patients receiving rituximab, reinforced pneumococcal vaccination strategies improved humoral immunogenicity compared with the standard regimen (ClinicalTrials.gov Identifier: NCT03069703).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.